Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apimeds Pharmaceuticals US, Inc. Common Stock (NY:APUS)

0.6600 +0.0200 (+3.13%)
Official Closing Price Updated: 6:30 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Apimeds Pharmaceuticals US, Inc. Common Stock

TechMediaBreaks – MindWave Innovations Inc. (NYSE American: APUS) Bridging Gap Between Traditional Finance and Web3
Via Investor Brand Network
Topics Artificial Intelligence
The Next Generation of Treasury Management: How MindWave Innovations Inc. (NYSE American: APUS) Is Building for Programmable Corporate Reserves
Via Investor Brand Network
Topics Bonds
MissionIRNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Advancing Platform for Institutional Bitcoin Treasury Strategies
Via Investor Brand Network
Bridging Traditional Finance and Web3: MindWave Innovations Inc.’s (NYSE American: APUS) Vision for Corporate Digital Asset Treasuries
Via Investor Brand Network
Topics Economy
TechMediaBreaks – MindWave Innovations Inc. (NYSE American: APUS) Integrates AI, Blockchain to Optimize Digital Asset Treasury Management
Via Investor Brand Network
Topics Artificial Intelligence Economy
From Ownership to Utility: How Digital Assets Are Becoming Productive Capital
Via CryptoCurrencyWire
From Ownership to Utility: How Digital Assets Are Becoming Productive Capital
Via Investor Brand Network
MissionIRNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Offers Secure Gateway to Digital Assets
Via Investor Brand Network
MindWave Innovations Inc. (NYSE American: APUS) Is Building an Ecosystem Designed to Unlock the Full Potential of Digital Asset Treasury Management
Via Investor Brand Network
Topics Artificial Intelligence Economy
TechMediaBreaks – MindWave Innovations Inc. (NYSE American: APUS) Taps Growing Demand for Yield-Generating Solutions
Via Investor Brand Network
MindWave Innovations Inc. (NYSE American: APUS) Builds Institutional Bridge for Bitcoin Treasury Adoption
Via Investor Brand Network
Topics Economy
Bitcoin as a Corporate Treasury Asset: How MindWave Innovations Inc. (NYSE American: APUS) Is Redefining Institutional Yield Infrastructure
Via Investor Brand Network
Topics Artificial Intelligence Economy
The Infrastructure Gap Behind Corporate Bitcoin Adoption
Via Investor Brand Network
News headline image
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
From The Rosen Law Firm, P.A.
Via Business Wire
MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
Via CryptoCurrencyWire
Topics Artificial Intelligence Economy
MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence Economy
News headline image
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
From Apimeds Pharmaceuticals US, Inc.
Via GlobeNewswire
News headline image
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
From Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.